If pancreatitis is suspected, Wegovy should be discontinued and appropriate diagnostic tests performed urgently Gallbladder problems : Rapid weight loss increases risk of gallstone formation, with cholelithiasis reported in approximately 1.6% of Wegovy users Intestinal obstruction/ileus : Cases have been reported in post-marketing surveillance, particularly in patients with pre-existing GI conditions Management strategies recommended by healthcare professionals include: Eating smaller, more frequent meals rather than large portions Avoiding high-fat, spicy, or heavily processed foods Staying well-hydrated, particularly if experiencing diarrhoea or vomiting, to prevent dehydration and potential acute kidney injury Not lying down immediately after eating to minimise reflux Ensuring adequate fibre intake to prevent constipation Taking the medication on the same day each week to maintain steady levels Most GI side effects improve over time as the body adjusts to the medication, typically becoming less troublesome after 4-8 weeks at each dose level

Hot flashes are distressing vasomotor symptoms primarily caused by declining estrogen levels during menopause, affecting quality of life for millions of women
Findings GLP-1 RAs exhibit potential beneficial effects on depressive symptoms, cognitive function, and reduced risk of suicidal ideation in animal and human models through antioxidative, anti-inflammatory mechanisms, and modulation of neurotransmitter pathways
GLP-1 stimulates your body to release insulin, a hormone that helps move glucose, or sugar, from your blood into your cells for energy